www.sgtreport.com
FDA Approves Merck RSV Shot for Infants — Despite High Rates of Serious Reactions
by Dr. Joseph Mercola, Mercola: Story at-a-glance Merck’s respiratory syncytial virus (RSV) shot clesrovimab (Enflonsia) was approved even though 11.71% of babies in the trial experienced serious adverse events, including seizures, brain injury, and death Infants who got clesrovimab had a 350% higher risk of upper respiratory infections — exactly the type of illness this […]
New Posts (Home)
ChatBox
Popular Posts 
Game Zone
Top PodCasts
